THC Biomed Intl Ltd. engages in the research, development, production, and sale of cannabis products in Canada. The company offers cannabis consumables, including beverage drinks, gummies, baked goods, pre-rolls, sticks, and clones under the THC Kiss brand name; and genetic strains under the THC BioMed brand name. It also provides dry flowers under the Smoke That Thunders brand name; buds under th...
THC Biomed Intl reported revenue of 3.34 million CAD for fiscal year 2022, down 11.5% from fiscal year 2021, and net income of -3.07 million CAD. In Q3 2023 (the quarter ended April 30, 2023) revenue was 476,230 CAD, down 31.9% from a year before. Its market capitalization was $163,938 as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended July 31, 2022; market data as of October 9, 2026.
No profile data available.